Leqembi® Iqlik™ (lecanemab-irmb) supplemental Biologics License Application regarding subcutaneous starting dose granted Priority Review by the US FDA

BioArctic AB's (publ) (STO: BIOA B) partner Eisai announced today that the supplemental Biologics License Application (sBLA) for Leqembi Iqlik subcutaneous autoinjector (SC-AI) as a weekly starting ...
Le Lézard

Leqembi® Iqliktm (lecanemab-irmb) supplemental Biologics License Application regarding subcutaneous starting dose granted Priority Review by the US FDA

BioArctic AB's (publ) (STO: BIOA B) partner Eisai announced today that the supplemental Biologics License Application (sBLA) ...

Biovica International: Strong DiviTum TKa Results Published in JCO Precision Oncology

UPPSALA, SE / ACCESS Newswire / January 27, 2026 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II), a leader in blood-based cancer monitoring, today announced that DiviTum TKa data from th ...

FluoGuide Submits an IND for FG001, to Initiate First U.S. Registration Trial

KØBENHAVN, DK / ACCESS Newswire / January 21, 2026 / FluoGuide A/S ("FluoGuide" or the "Company")(STO:FLUO), a biotech ...
Le Lézard

Nexdata Announces Completion and Full Operation of Its World-Class Embodied AI Data Collection Factory

As embodied AI rapidly evolves from foundation models and software-based agents toward real-world intelligent robots, the industry is facing a critical bottleneck: the large-scale availability of high ...
Process and Control Today

Delta Expands ASDA-A3 Series with New EP Servo Drive for Safety-Critical Motion Control

The leading and longest established online Process Engineering publication serving the Process Manufacturing Industries ...
PharmiWeb

Strong DiviTum TKa Results Published in JCO Precision Oncology

UPPSALA, SE / ACCESS Newswire / January 27, 2026 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II), a leader in blood-based cancer monitoring, today announced that DiviTum TKa data from ...
PharmiWeb

Year-End Report 2025

GOTHENBURG, SE / ACCESS Newswire / January 27, 2026 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV)Fourth quarter 2025 (Oct-Dec)Net sales amounted to SEK 226.1 million (227.6), corresponding to ...